Page 29 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

Table 4: Summary of trials assessing symptoms and behavioral disturbances

Author, Year Mean N Duration Disease Results Quality
Age (weeks) Severity Rating
(years)
Donepezil vs. Galantamine
Wilcock et al., 73 188 52 NR Symptoms: No significant differences in N/A*
27
2003 cognition
Behavior / function: No significant
differences in behavior, measures of
daily functioning, or caregiver burden
Jones et al., 2004 28 74 120 12 Mild - Symptoms: significantly better cognitive N/A*
moderate scores for DON-treated patients
Behavior / function: Significantly better
physician & caregiver satisfaction and
less disability for DON-treated patients
Donepezil vs. Rivastigmine
Wilkinson et al., 74 111 12 Mild - Symptoms: No significant differences in N/A*
29
2002 moderate cognition
Behavior / function: Clinician and
caregiver satisfaction significantly
better with DON
Donepezil, Galantamine, and Rivastigmine vs. Placebo
Lanctot et al., 2003 NR 7954 ≥ 12 NR Symptoms: Pooled NNT to yield one Good
30
(MA) weeks additional ChEI global responder was
12; NNT to yield one additional
cognitive responder was 10
Behavior / function: NR
Kaduszkiewicz et al., NR 9030 ≥ 6 NR Symptoms: small beneficial effects for Fair
31
2005 (MA) weeks ChEI compared to placebo; the mean
difference was 1.5 to 3.9 points for the
ADAS-cog and 0.26 to 0.54 points for
the CIBIC-plus
Behavior / function: NR
Donepezil vs. Placebo
Birks, 2004 (MA) 32 NR 436 > 12 Mild – Symptoms: significantly better cognitive Good
5 moderate and global assessment scores for DON
Behavior / function: no differences in
QoL and functional capacity
Whitehead et al., NR 237 12-24 Mild - Symptoms: significantly better ADAS- Fair
33
2004 (MA) 6 moderate cog scores for DON treated patients
Behavior / function: no difference in QoL
AD2000** 38 76 565 192 Mild - Symptoms: significantly better cognition Fair
moderate scores for DON
Behavior / function: no differences in
rates of institutionalization and
progression of functional decline
Burns et al., 1999 39 72 818 24 Mild - Symptoms: significantly better cognitive Fair
moderate and global assessment scores for DON
Behavior / function: no difference in QoL
Feldman et al., 74 290 24 Moderate Symptoms: significantly better cognitive Good
2001 40, 71-73 - severe and global assessment scores for DON
Behavior / function: slower decline of
measures of daily functioning for DON
Homma et al., 70 268 24 Mild - Symptoms: significantly better cognitive Fair
41
2000 moderate and global assessment scores for DON
Behavior / function: slower decline of
function in DON patients

Alzheimer's Drugs Page 29 of 205